drugset / Trial / NCT00336505

Study Comparing the Safety and Efficacy of Cethromycin to Clarithromycin for the Treatment of Community-Acquired Pneumonia (CAP)

NCT00336505

Phase 3 Completed 584 enrolled Advanced Life Sciences, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to compare the efficacy of cethromycin to clarithromycin for the treatment of mild to moderate community-acquired pneumonia (CAP).

Timeline

Start
2005-12
Primary completion
2007-10
Completion
2007-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Cethromycin Small molecule 300 mg Oral
Comparator Clarithromycin Small molecule 250 mg Oral

Indications